RU2017103679A - Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение - Google Patents
Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение Download PDFInfo
- Publication number
- RU2017103679A RU2017103679A RU2017103679A RU2017103679A RU2017103679A RU 2017103679 A RU2017103679 A RU 2017103679A RU 2017103679 A RU2017103679 A RU 2017103679A RU 2017103679 A RU2017103679 A RU 2017103679A RU 2017103679 A RU2017103679 A RU 2017103679A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- variable region
- antibody
- acid sequence
- cytosol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 22
- 210000000172 cytosol Anatomy 0.000 title claims 18
- 230000002401 inhibitory effect Effects 0.000 title claims 3
- 230000003834 intracellular effect Effects 0.000 title claims 2
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 235000001014 amino acid Nutrition 0.000 claims 12
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000004474 valine Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000002502 liposome Substances 0.000 claims 3
- 239000002105 nanoparticle Substances 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 230000012202 endocytosis Effects 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 230000004807 localization Effects 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140092687 | 2014-07-22 | ||
| KR10-2014-0092687 | 2014-07-22 | ||
| KR10-2015-0103214 | 2015-07-21 | ||
| KR1020150103214A KR101602876B1 (ko) | 2014-07-22 | 2015-07-21 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| PCT/KR2015/007627 WO2016013871A1 (ko) | 2014-07-22 | 2015-07-22 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017103679A true RU2017103679A (ru) | 2018-08-06 |
Family
ID=55354089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017103679A RU2017103679A (ru) | 2014-07-22 | 2015-07-22 | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10851177B2 (enExample) |
| EP (1) | EP3173099B1 (enExample) |
| JP (1) | JP6798988B2 (enExample) |
| KR (2) | KR101602876B1 (enExample) |
| CN (1) | CN106999575A (enExample) |
| AU (1) | AU2015292956B2 (enExample) |
| BR (1) | BR112017001306A2 (enExample) |
| CA (1) | CA2955265A1 (enExample) |
| IL (1) | IL250137B (enExample) |
| MX (1) | MX2017001012A (enExample) |
| RU (1) | RU2017103679A (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| CA3025757A1 (en) | 2016-05-27 | 2017-11-30 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
| EP3712180A4 (en) * | 2017-11-16 | 2021-08-11 | Orum Therapeutics Inc. | RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
| JP2021532135A (ja) * | 2018-07-23 | 2021-11-25 | 中外製薬株式会社 | 標的細胞特異的な細胞質侵入抗原結合分子 |
| KR20200088780A (ko) * | 2019-01-15 | 2020-07-23 | 오름테라퓨틱 주식회사 | 세포질 침투성이 증진된 항체 |
| US20220177603A1 (en) * | 2019-05-01 | 2022-06-09 | Universidade De Santiago De Compostela | Intracellular delivery of anti-kras antibodies formulated into nanocapsules |
| TW202204420A (zh) * | 2020-04-30 | 2022-02-01 | 美商建南德克公司 | Ｋｒａｓ特異性抗體及其用途 |
| IL307396A (en) * | 2021-04-02 | 2023-12-01 | Massachusetts Gen Hospital | Methods for inhibiting RAS |
| CN117916258A (zh) | 2021-07-20 | 2024-04-19 | 亚洲大学校产学协力团 | 穿透进细胞以降解和去除靶蛋白的细胞穿透降解抗体及其用途 |
| US20250122308A1 (en) * | 2021-09-17 | 2025-04-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeting mutant kras with a mutation specific iga |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| CN1241574A (zh) | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
| AU2003219277A1 (en) * | 2002-03-14 | 2003-09-29 | Medical Research Council | Intracellular antibodies |
| GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| WO2004046188A2 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
| KR20090008290A (ko) * | 2006-03-27 | 2009-01-21 | 글로브이뮨 | Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법 |
| MX2010007357A (es) | 2008-01-03 | 2011-03-03 | The Scripps Res Institute Star | Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular. |
| KR100849941B1 (ko) * | 2008-04-29 | 2008-08-01 | 원우이에프엔지니어링주식회사 | 열 및 연기 화재감지장치 복합시험기 |
| US20110159569A1 (en) * | 2008-04-30 | 2011-06-30 | Ajou University IndustryAcademic Cooperation Found | Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same |
| KR101075123B1 (ko) * | 2008-10-24 | 2011-10-19 | 아주대학교산학협력단 | 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도 |
| CN102209726A (zh) | 2008-11-11 | 2011-10-05 | 亚州大学校产学协力团 | 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物 |
| CN101402675B (zh) | 2008-11-28 | 2012-05-30 | 中国人民解放军第三军医大学第三附属医院 | 一种靶向抑制ανβ3阳性细胞增殖的环肽 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| GB201103631D0 (en) * | 2011-03-03 | 2011-04-13 | Univ Leeds | Identification of candidate therapeutics |
| WO2012135831A1 (en) | 2011-04-01 | 2012-10-04 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2014042209A1 (ja) | 2012-09-14 | 2014-03-20 | 公益財団法人がん研究会 | ＥｐＣＡＭに結合するペプチド |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| WO2016013870A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| EP3277314A4 (en) | 2015-04-03 | 2018-08-29 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
| KR101790669B1 (ko) | 2015-10-14 | 2017-10-26 | 아주대학교산학협력단 | 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도 |
| CA3025757A1 (en) | 2016-05-27 | 2017-11-30 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
| KR101836392B1 (ko) | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물 |
| EP3712180A4 (en) | 2017-11-16 | 2021-08-11 | Orum Therapeutics Inc. | RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
-
2015
- 2015-07-21 KR KR1020150103214A patent/KR101602876B1/ko not_active Expired - Fee Related
- 2015-07-22 JP JP2017525496A patent/JP6798988B2/ja not_active Expired - Fee Related
- 2015-07-22 BR BR112017001306-1A patent/BR112017001306A2/pt not_active Application Discontinuation
- 2015-07-22 EP EP15825508.3A patent/EP3173099B1/en active Active
- 2015-07-22 MX MX2017001012A patent/MX2017001012A/es unknown
- 2015-07-22 RU RU2017103679A patent/RU2017103679A/ru not_active Application Discontinuation
- 2015-07-22 AU AU2015292956A patent/AU2015292956B2/en not_active Ceased
- 2015-07-22 CN CN201580045140.3A patent/CN106999575A/zh active Pending
- 2015-07-22 CA CA2955265A patent/CA2955265A1/en not_active Abandoned
- 2015-07-22 US US15/327,539 patent/US10851177B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 KR KR1020160016637A patent/KR101732553B1/ko not_active Expired - Fee Related
-
2017
- 2017-01-16 IL IL250137A patent/IL250137B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US10851177B2 (en) | 2020-12-01 |
| KR20160033670A (ko) | 2016-03-28 |
| CA2955265A1 (en) | 2016-01-28 |
| AU2015292956A1 (en) | 2017-02-09 |
| AU2015292956B2 (en) | 2020-04-02 |
| MX2017001012A (es) | 2018-06-19 |
| KR101732553B1 (ko) | 2017-05-08 |
| BR112017001306A2 (pt) | 2018-01-30 |
| KR20160011599A (ko) | 2016-02-01 |
| IL250137A0 (en) | 2017-03-30 |
| US20170158777A1 (en) | 2017-06-08 |
| JP2017529870A (ja) | 2017-10-12 |
| KR101602876B1 (ko) | 2016-03-11 |
| EP3173099B1 (en) | 2020-03-04 |
| EP3173099A1 (en) | 2017-05-31 |
| JP6798988B2 (ja) | 2020-12-09 |
| EP3173099A4 (en) | 2018-03-14 |
| IL250137B (en) | 2020-05-31 |
| CN106999575A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017103679A (ru) | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение | |
| RU2017103675A (ru) | Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| JP2017529097A5 (enExample) | ||
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2014511179A5 (enExample) | ||
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| JP2015522252A5 (enExample) | ||
| FI2691417T4 (fi) | Vasta-aineen Fc-variantteja | |
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| RU2012149227A (ru) | Биологические материалы, относящиеся к her3 | |
| PE20181363A1 (es) | Variantes optimizadas de anticuerpos anti-vegf | |
| RU2017104642A (ru) | Новое антитело против tie-2 человека | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2014534806A5 (enExample) | ||
| JP2017529870A5 (enExample) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| RU2015102069A (ru) | Антитела к биотину и способы их применения | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения | |
| JP2016512214A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180723 |